TY - JOUR
T1 - Ex vivo stimulation of the trigeminal nucleus caudalis induces peripheral CGRP release in the trigeminal ganglion and reveals a distinct dopamine-endocannabinoid mechanism relevant to migraine
AU - Christiansen, Isabella Mai
AU - Reducha, Philip Victor
AU - Edvinsson, Lars
AU - Holm, Anja
AU - Haanes, Kristian Agmund
N1 - © 2025. The Author(s).
PY - 2025/6/16
Y1 - 2025/6/16
N2 - BACKGROUND: Calcitonin gene-related peptide (CGRP) release from trigeminal structures is central to migraine pathophysiology. This study employed an ex vivo model preserving anatomical continuity between the trigeminal nucleus caudalis (TNC) and trigeminal ganglion (TG) to investigate (1) whether TNC stimulation induces peripheral CGRP release from the TG and (2) the potential involvement of a distinct dopamine-endocannabinoid mechanism.METHODS: Tissues were dissected as a single unit and placed in custom 3D-printed chambers, allowing targeted stimulation of either the TNC or the TG while measuring CGRP in both compartments. Pharmacological tools, including capsaicin (TRPV1 agonist), KCl (depolarizing agent), dopamine, and selective enzyme inhibitors or receptor antagonists, were used to elucidate underlying signalling pathways. CGRP levels were quantified via enzyme-linked immunosorbent assay.RESULTS: Stimulation of the TNC elicited a significant rise in CGRP release locally and in the TG compartment, whereas directly stimulating the TG did not trigger CGRP release in the TNC. Subsequent experiments showed that applying dopamine to the TNC further enhanced CGRP release. TRPV1 blockade or pharmacological inhibition of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), an enzyme important for anandamide biosynthesis, markedly attenuated dopamine-induced CGRP release, indicating that an endocannabinoid-driven mechanism is involved.CONCLUSION: Activating the TNC alone was sufficient to evoke CGRP release in the peripheral trigeminal compartment, underscoring a potential central-to-peripheral mechanism that may be relevant to migraine. Moreover, a dopamine-endocannabinoid-TRPV1 axis appears to modulate CGRP signalling in this system, indicating additional complexity and providing potential new strategies for migraine therapy.
AB - BACKGROUND: Calcitonin gene-related peptide (CGRP) release from trigeminal structures is central to migraine pathophysiology. This study employed an ex vivo model preserving anatomical continuity between the trigeminal nucleus caudalis (TNC) and trigeminal ganglion (TG) to investigate (1) whether TNC stimulation induces peripheral CGRP release from the TG and (2) the potential involvement of a distinct dopamine-endocannabinoid mechanism.METHODS: Tissues were dissected as a single unit and placed in custom 3D-printed chambers, allowing targeted stimulation of either the TNC or the TG while measuring CGRP in both compartments. Pharmacological tools, including capsaicin (TRPV1 agonist), KCl (depolarizing agent), dopamine, and selective enzyme inhibitors or receptor antagonists, were used to elucidate underlying signalling pathways. CGRP levels were quantified via enzyme-linked immunosorbent assay.RESULTS: Stimulation of the TNC elicited a significant rise in CGRP release locally and in the TG compartment, whereas directly stimulating the TG did not trigger CGRP release in the TNC. Subsequent experiments showed that applying dopamine to the TNC further enhanced CGRP release. TRPV1 blockade or pharmacological inhibition of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), an enzyme important for anandamide biosynthesis, markedly attenuated dopamine-induced CGRP release, indicating that an endocannabinoid-driven mechanism is involved.CONCLUSION: Activating the TNC alone was sufficient to evoke CGRP release in the peripheral trigeminal compartment, underscoring a potential central-to-peripheral mechanism that may be relevant to migraine. Moreover, a dopamine-endocannabinoid-TRPV1 axis appears to modulate CGRP signalling in this system, indicating additional complexity and providing potential new strategies for migraine therapy.
KW - Calcitonin Gene-Related Peptide/metabolism
KW - Animals
KW - Dopamine/metabolism
KW - Trigeminal Ganglion/metabolism
KW - Endocannabinoids/metabolism
KW - Migraine Disorders/metabolism
KW - TRPV Cation Channels/metabolism
KW - Male
KW - Rats
KW - Capsaicin/pharmacology
KW - Trigeminal Caudal Nucleus/metabolism
KW - Dopamine
KW - Trigeminal nucleus caudalis
KW - Migraine
KW - Ex vivo model
KW - TRPV1
KW - Calcitonin gene-related peptide
KW - Endocannabinoid system
KW - Trigeminal ganglion
UR - http://www.scopus.com/inward/record.url?scp=105008110962&partnerID=8YFLogxK
U2 - 10.1186/s10194-025-02072-6
DO - 10.1186/s10194-025-02072-6
M3 - Journal article
C2 - 40524163
SN - 1129-2377
VL - 26
JO - The Journal of Headache and Pain Online
JF - The Journal of Headache and Pain Online
IS - 1
M1 - 141
ER -